Developed by YL Biologics, a joint venture between Lupin's subsidiary Lupin Atlantis Holdings SA(LAHSA) and Yoshindo, the product will be launched by Nichi-lko after receiving approval from the Pharmaceuticals and Medical Devices Agency (PMDA).
Powered by Capital Market - Live News